In the News

Elisabeth B. Wilson, MD, MPH, MS-HPEd

Elisabeth B. Wilson, MD, joins D-HH and Dartmouth’s Geisel School of Medicine as new chair of the Department of Community and Family Medicine

Dr. Wilson has accepted the role as chair and professor of the Department of Community and Family Medicine for the D-HH system and Dartmouth’s Geisel School of Medicine. She begins her role in March 2022 and will succeed Cathleen Morrow, MD as chair.

View story

Photo of top of building.

New Vice Chair of Research for Obstetrics and Gynecology Named at Dartmouth-Hitchcock Health

D-HH has named Daisy Goodman, DNP, MPH, CARN-AP, APRN, CNM, as the vice chair of Research for Obstetrics and Gynecology (OB/GYN).

View story

Photo of women walking down a hallway with helper.

Dartmouth-Hitchcock Health Increases Minimum Wage to $17 per Hour

Responding to labor shortage, health system makes second major minimum wage adjustment in nine months

View story

Heads Up: Coping through COVID-19

D-HH Launches Third Installment of its Virtual Roundtable Series as Effects of COVID-19 Pandemic Continue

“Heads Up: Coping Through COVID-19” is a pre-recorded series of virtual conversations featuring D-HH mental health experts, community partners and other experts offering information and tips for people of all ages

View story

Tom Manion, New London Hospital (NLH) President and CEO

Message to the Community - September 2, 2021

Tom Manion, NLH President and CEO addresses the recent rise in emergency department and inpatient visits, the impact of staffing shortages and an update on Express Care.

View story

D-HH Chief Clinical Officer Edward J. Merrens, MD

D-HH Continues to Adapt to Rapidly Changing Health Care Landscape as COVID-19 Pandemic Rages On

National staffing crisis, pandemic resurgence have increased local impacts; health providers ask for understanding and patience as they make the best, difficult decisions to ensure excellent care

View story

COVID-19 vaccine

D-HH Answers Questions about Third COVID-19 Vaccine Dose for Immunocompromised People

The U.S. Food and Drug Administration (FDA) authorized the use of a third dose of the Pfizer and Moderna COVID-19 vaccines for immunocompromised people, with the third dose to be administered at least 28 days following the first two doses.

View story